Articles tagged with Hiv Research
Researchers found that the HIV protein vpu interferes with the immune response protein IRF3, dampening the ability of the immune system to protect against virus infection. This discovery could lead to the development of new antiviral therapeutics that target this interaction.
The Lifespan/Tufts/Brown Center for AIDS Research has received a $8.5 million, five-year renewal grant from the National Institutes of Health to support interdisciplinary collaboration and shared resources among over 60 investigators from various fields.
Adding nevirapine to the regimen of newborns born to HIV-positive mothers halves their risk of contracting the virus, according to a recent study. The research found that the two-drug combination is effective in preventing mother-to-child HIV transmission and is relatively easy to administer.
A recent NIH study reveals that children born with HIV are more likely to experience hearing loss by age 16. The researchers estimated that 9-15% of HIV-infected children and 5-8% of uninfected peers may be affected.
A recent NIH study found that HIV-positive young men are more likely to experience low bone mass than their peers. Regular monitoring, exercise, and sufficient vitamin D intake can help prevent future fracture risk. The study's findings highlight the importance of addressing bone health in this vulnerable population.
The HIV Prevention Trials Network (HPTN) 052 study faced significant ethical challenges as it investigated the use of antiretroviral treatment to prevent sexual transmission of HIV. The trial's findings provide valuable insights into managing ethical difficulties in research, while also shedding light on the importance of balancing sci...
A study by University of North Carolina researchers found that breast milk has a strong virus-killing effect and protects against oral transmission of HIV. The 'BLT' mouse model was used to demonstrate this, with the oral cavity and upper digestive tract of mice mimicking human cells affected by HIV transmission.
A clinical trial found that nevirapine-based treatment was as effective as lopinavir/ritonavir in controlling HIV levels and reducing mortality among African women. The study confirms the affordability and efficacy of nevirapine-based treatment regimens for initial HIV treatment in resource-limited settings.
A new study in Uganda found that HIV superinfection may be more common than previously thought, occurring at a rate comparable to the annual incidence of new HIV infections. The research suggests that post-test counseling should emphasize the risk of superinfection and its implications for public health strategies.
A new project aims to increase hearing aid use by providing easy-to-use video tutorials that address common barriers to adoption. The tutorials offer practical tips, animations, and real-life experiences from users to support patients in making the most of their devices.
Researchers from Microbicide Trials Network reformulated tenofovir gel to reduce glycerin content, making it safer and more effective for rectal use. The new formulation is three times less likely to cause cells to release water and equally effective against HIV as the original vaginal formulation.
A new study by Stanford University School of Medicine researchers found that the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) contributed to a significant decline in adult death rates from all causes in Africa. The program saved over 740,000 lives between 2004 and 2008 in nine countries targeted by PEPFAR.
Researchers conducted a 10-year retrospective study on HIV patients in San Francisco, finding that they suffered sudden cardiac death at a rate four times higher than the general population. The study suggests that HIV changes the electrophysiology of the heart, increasing the risk of conduction abnormalities and sudden death.
Male study participants who received an experimental HIV vaccine were at higher risk of infection due to neutralizing antibodies to Ad5 or being uncircumcised. However, the risk level decreased over time and was equal to that of volunteers who received a placebo after about 18 months.
Researchers describe a novel mechanism of HIV-1 spread by dendritic cells, using a molecule called GM3 for attachment and spread. This unique contact between HIV-1 and dendritic cells may offer a new direction for anti-viral therapies, as drugs targeting this interaction could have the benefit of acting on the host.
Researchers found an increase in condom use among participants on longitudinal follow-up at six-month and 12-month intervals. Males, older patients, and HIV-positive patients were more likely to use condoms in their sexual encounters.
African-led initiative calls for increased research and advocacy on rectal microbicides to address the growing issue of unprotected anal intercourse in Africa, which is 10-20 times more likely to result in HIV infection than unprotected vaginal intercourse.
A daily pill to prevent HIV infection is cost-effective for men at high risk of acquiring the virus, according to a Stanford University study. The researchers found that targeted use of the drug in this population could save $495 billion over 20 years compared to widespread use.
The conference presents promising results from anti-retroviral based microbicides and pre-exposure prophylaxis (PrEP) with potential to end the AIDS epidemic. Key findings highlight the need for diverse approaches, adherence, risk perception, and delivery of PrEP options to high-risk populations.
A team of UCLA researchers demonstrates that genetically engineered human blood stem cells can form mature, multi-functional T cells that specifically target HIV-infected cells. This approach shows promise for suppressing the virus in living tissues in animal models.
A study analyzing blood samples from RV144 trial participants found that those with high levels of a certain antibody were less likely to get infected. Researchers believe this may indicate the need for a different type of immune response in an HIV vaccine, but further testing is needed.
Laboratory studies of the RV144 vaccine have found that antibodies specific to a particular region of the HIV outer coat correlate with lower infection rates among vaccinated individuals. In contrast, high levels of a different type of envelope binding antibody appear to offer less protection against HIV.
Researchers analyzed immune responses in RV144 trial participants and found that antibodies specific to the V1V2 region correlated with lower infection rates. Vaccine recipients with high levels of IgA envelope protein binding antibody had less protection from HIV than those with low levels.
Researchers argue that incentives can encourage participants to engage in healthy behaviors when properly designed and evidence-based. The authors propose that Research Ethics Committees require an evidence-based rationale for predicting incentive effectiveness.
A recent study published in PLOS Medicine argues that the use of cash incentives to promote healthy behaviors may not be as problematic as previously thought. The authors suggest that when incentives are used to encourage people to engage in activities they are already familiar with and likely to benefit from, ethical concerns may be m...
A study found that only three out of 187 syringe exchange programs received federal funding, citing barriers to accessing funds due to local law enforcement requirements and guidelines. The researchers advocate for easier access to federal funding and call for legislative support to maximize public health benefit
Researchers at Johns Hopkins Bloomberg School of Public Health found that female sex workers are nearly 14 times more likely to be infected with HIV compared to the general population. The analysis of 102 previous studies representing almost 100,000 female sex workers in 50 countries revealed a significant disparity in HIV prevalence a...
A two-year Duke University study found that over half of patients had experienced sexual or physical abuse in their lifetime, leading to worse medical outcomes and poorer health-related behaviors. Childhood trauma was also associated with instances of unprotected sex, missing antiretroviral medications, and recent emergency room visits.
SIV's natural hosts, non-human primates, display a unique immune response to the virus, characterized by low immune activation and efficient preservation of immune cells. This study suggests that understanding these adaptations could inform medical care for people living with HIV.
A clinical trial shows that interferon-alpha can control HIV replication in patients who stop antiretroviral therapy, reducing integrated HIV DNA levels and decreasing reservoirs. The study provides hope for a functional cure and opens the way to further research on HIV eradication.
Scientists at Emory University and GeoVax Labs developed a vaccine that protected nonhuman primates against multiple SIV exposures over three years. The vaccine regimen included a DNA prime vaccine with GM-CSF, which enhanced immune responses and provided 70-84% overall protection.
Two NIH-funded studies demonstrate the benefits of immediate antiretroviral treatment for HIV-infected infants, showing improved survival rates and healthier brain development. The studies found that treating infants with ART within the first year of life significantly reduced the risk of death and disease progression.
A recent US study found that only about 75% of HIV/AIDS patients in the United States remain in consistent care, with long gaps between appointments common. Patients with certain characteristics, such as women, white patients, and those with low CD4 counts, are more likely to stay in care.
A Phase I clinical study has confirmed that a new rectal formulation of tenofovir gel is safe and well-tolerated when used daily for one week. The gel, designed to reduce glycerin levels, showed promise in preventing HIV transmission from anal sex, with high adherence rates among participants.
A new research collection highlights the prevalence of improper condom use worldwide, citing common challenges in the US and globally. The study emphasizes the need for improved education and access to condoms to reduce unplanned pregnancies and STIs.
A researcher at Indiana University has discovered a compound that could counteract HIV's ability to hijack the immune system's protection mechanism. The compound, which binds to the CD59 protein, enables antibodies and complement proteins to attack infected cells instead of just viral particles.
Researchers have discovered a mechanism by which the immune system tries to halt HIV's spread, focusing on a protein called SAMHD1 that protects cells from viral hijacking. By understanding this mechanism, scientists may find new ways to stop or slow the virus' ability to infect.
A team of researchers has discovered how the protein SAMHD1 protects immune cells from HIV by starving the virus of necessary building blocks. This finding could lead to more effective anti-HIV drugs and new insights into other viral infections.
Researchers analyzed data from an observational study to examine the relationship between HIV illness severity and psychiatric disorders. The study found limited evidence of associations between specific antiretroviral therapy and psychiatric symptoms, but noted associations with quality of life and cognitive functioning.
A Wayne State University researcher is working to promote HIV testing among African-Americans by expanding testing in county jails. Her team provides comprehensive HIV prevention services, including counseling and referrals for those who test positive.
Five Portuguese scientists have been awarded prestigious funding by the US-based HHMI for their innovative research projects. The awardees, who are based in Portugal, will receive $650,000 over five years to work on diverse areas of neuroscience and parasitology.
New research aims to create algorithms mimicking human brain sound processing to enhance speech intelligibility in noisy situations. The goal is to develop a brain-inspired speech enhancer that can identify sound sources and reduce the stigma associated with hearing aids.
A recent study published in Nature shows that a novel combination of HIV vaccine candidates provides partial protection against Simian Immunodeficiency Virus (SIV) infection in rhesus monkeys. The optimal vaccine combinations also substantially reduced the amount of virus in the blood.
A groundbreaking clinical trial has demonstrated that antiretroviral drugs can provide both treatment and prevention for HIV, reducing transmission rates by up to 96%. The study found that treated individuals are significantly less likely to infect their partners.
The HPTN 052 study found that early treatment with antiretroviral therapy can reduce HIV transmission in couples by at least 96%. The research has been recognized as a scientific breakthrough of the year, inspiring efforts to end the world's AIDS epidemic.
A study by Rhode Island Hospital researchers found a 74 percent greater risk of overdose among HIV-infected drug users, attributed to biological and behavioral factors. The study suggests that access to medication-assisted therapy, highly active antiretroviral therapy, and naloxone can help reduce this increased risk.
A study published in PLOS ONE found that Danish HIV patients with optimal treatment can live as long as the general population. The study, which has been tracking HIV patients for over 15 years, shows that patients are not as ill on diagnosis and have higher CD4 cell counts. This suggests that early treatment and better care may be con...
Researchers at Caltech have successfully delivered neutralizing antibodies to mice using Vectored ImmunoProphylaxis (VIP), a novel approach to HIV prevention. The treatment effectively protected the mice from HIV infection and produced high concentrations of broadly neutralizing antibodies that may translate to human protection.
A Scripps Florida scientist has received a $3.4 million grant to study a new compound that blocks HIV replication by targeting the viral protein Tat. The goal is to evaluate its therapeutic potential in animal models and optimize it for human clinical trials, potentially leading to a novel class of anti-viral drugs.
The Vaginal and Oral Interventions to Control the Epidemic (VOICE) study found that daily use of an antiretroviral-containing oral tablet or vaginal gel was not effective in preventing HIV infection among women. The study will continue to examine the safety and effectiveness of oral Truvada as a preventive measure for women.
Mayo Clinic has been awarded a $1.25 million grant by the Centers for Disease Control and Prevention (CDC) to develop online medical education in Ethiopia.
A topical gel containing an anti-HIV drug was found to be safe and effective in reducing HIV infection when applied to rectal tissue exposed to HIV. The study suggests a significant reduction in HIV transmission, particularly for receptive anal intercourse, which accounts for a major route of new infections.
A Wayne State University researcher is conducting studies to understand the differences in marijuana use among three subgroups of HIV-positive patients. The goal is to address knowledge gaps and inform decision-making at a state level, potentially guiding treatment and policy.
A team of Caltech biologists has developed a new, more potent HIV antibody that targets the virus's entry site. The antibody shows increased effectiveness against multiple subtypes of HIV, paving the way for potential clinical testing and improved vaccine development.
A novel molecular mechanism discovered by Bruce Beutler and colleagues suggests that the body's molecular sensors may trigger autoimmune disease. The researchers' findings have important implications for understanding the initiation of both protective and inflammatory immune responses, as well as autoimmune diseases.
A new standard definition for loss-to-follow-up (LTFU) has been established for HIV antiretroviral therapy patients, using a 180-day clinic visit threshold. This definition was developed based on statistical analysis of data from 111 health facilities across Africa, Asia, and Latin America.
Breakout Labs aims to accelerate revolutionary science by supporting independent scientists and early-stage companies with radical ideas. Funding is provided through a revolving fund, with successful projects contributing back to the program.
Starting HIV therapy two weeks after TB treatment increases survival by 33 percent, according to a recent study. The study suggests that immunosuppressed patients should be started on ART rapidly at two weeks after beginning TB therapy.
Researchers have discovered a highly effective antibody that can neutralize approximately 70% of globally circulating HIV strains by targeting the virus's envelope protein. The new findings suggest a promising target for AIDS vaccine development, with potential implications for broadening the protection against the fast-mutating virus.
Researchers have discovered two genetically distinct HIV types in the cerebrospinal fluid of patients with HIV-associated dementia, which may predict disease progression and cognitive damage. The study found that one variant infects macrophages, a type of white blood cell, while the other reproduces in T cells.